This inhibitor is used commercially in patients who develop idiopathic pulmonary fibrosis and acts on signaling pathways triggered by TNF-α and TGF-β, such as SMAD and MAPK signaling pathway proteins [52]. Here, TGFB1 is linked to idiopathic pulmonary fibrosis.